These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Loss of neurofibromin is associated with activation of RAS/MAPK and PI3-K/AKT signaling in a neurofibromatosis 1 astrocytoma. Lau N; Feldkamp MM; Roncari L; Loehr AH; Shannon P; Gutmann DH; Guha A J Neuropathol Exp Neurol; 2000 Sep; 59(9):759-67. PubMed ID: 11005256 [TBL] [Abstract][Full Text] [Related]
6. Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications. Gottfried ON; Viskochil DH; Couldwell WT Neurosurg Focus; 2010 Jan; 28(1):E8. PubMed ID: 20043723 [TBL] [Abstract][Full Text] [Related]
7. Genotype-phenotype associations in neurofibromatosis type 1 (NF1): an increased risk of tumor complications in patients with NF1 splice-site mutations? Alkindy A; Chuzhanova N; Kini U; Cooper DN; Upadhyaya M Hum Genomics; 2012 Aug; 6(1):12. PubMed ID: 23244495 [TBL] [Abstract][Full Text] [Related]
9. Neurological malignancies in neurofibromatosis type 1. Eoli M; Saletti V; Finocchiaro G Curr Opin Oncol; 2019 Nov; 31(6):554-561. PubMed ID: 31436563 [TBL] [Abstract][Full Text] [Related]
10. New Model Systems and the Development of Targeted Therapies for the Treatment of Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors. Williams KB; Largaespada DA Genes (Basel); 2020 Apr; 11(5):. PubMed ID: 32353955 [TBL] [Abstract][Full Text] [Related]
11. [Neurofibromatosis: the most frequent hereditary tumor predisposition syndrome]. Wimmer K Wien Med Wochenschr; 2005 Jun; 155(11-12):273-80. PubMed ID: 16035388 [TBL] [Abstract][Full Text] [Related]
15. [Neurofibromatosis type 1 and associated clinical abnormalities in 27 children]. Syrbe S; Eberle K; Strenge S; Bernhard MK; Herbertz S; Bierbach U; Hirsch W; Froster UG; Kiess W; Merkenschlager A Klin Padiatr; 2007; 219(6):326-32. PubMed ID: 18183640 [TBL] [Abstract][Full Text] [Related]
16. Characterization of the somatic mutational spectrum of the neurofibromatosis type 1 (NF1) gene in neurofibromatosis patients with benign and malignant tumors. Upadhyaya M; Han S; Consoli C; Majounie E; Horan M; Thomas NS; Potts C; Griffiths S; Ruggieri M; von Deimling A; Cooper DN Hum Mutat; 2004 Feb; 23(2):134-146. PubMed ID: 14722917 [TBL] [Abstract][Full Text] [Related]
17. Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors. Dasgupta B; Yi Y; Chen DY; Weber JD; Gutmann DH Cancer Res; 2005 Apr; 65(7):2755-60. PubMed ID: 15805275 [TBL] [Abstract][Full Text] [Related]
18. Insights into optic pathway glioma vision loss from mouse models of neurofibromatosis type 1. Freret ME; Gutmann DH J Neurosci Res; 2019 Jan; 97(1):45-56. PubMed ID: 29704429 [TBL] [Abstract][Full Text] [Related]
19. Cerebrospinal fluid proteomic analysis reveals dysregulation of methionine aminopeptidase-2 expression in human and mouse neurofibromatosis 1-associated glioma. Dasgupta B; Yi Y; Hegedus B; Weber JD; Gutmann DH Cancer Res; 2005 Nov; 65(21):9843-50. PubMed ID: 16267007 [TBL] [Abstract][Full Text] [Related]
20. Type I neurofibromatosis: a geno-oculo-dermatologic update. Schnur RE Curr Opin Ophthalmol; 2012 Sep; 23(5):364-72. PubMed ID: 22871881 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]